Design And Development Of A Novel Formulation Of Pacritinib For Treatment Of Adults Intermediate And High Risk Myelofibrosis With Low Platelet Count. Journal of Pharmaceutical Negative Results [Internet]. 2023 Jan. 15 [cited 2026 Jun. 13];:649-52. Available from: https://mail.pnrjournal.com/index.php/home/article/view/7066